Sorrento Therapeutics Inc SRNE

Healthcare Biotechnology

Sorrento Therapeutics, Inc. is a clinical and commercial stage biopharmaceutical company. The Company is engaged in developing new therapies to treat cancer, pain (non-opioid treatments), autoimmune diseases and COVID-19. The Company’s segments include Sorrento Therapeutics and Scilex. The Sorrento Therapeutics segment is organized around its Immune-Oncology therapeutic area, leveraging its G-MAB antibody library and targeted delivery modalities to generate the next-generation of cancer therapeutics. The Scilex segment is organized around its non-opioid pain management operations and clinical pipeline. The Company’s immuno-oncology platforms, including its fully human antibodies (G-MAB library), ACEA small molecule library, immuno-cellular therapies (DAR-T), antibody-drug conjugates (ADCs) and oncolytic virus (Seprehvec). The Company is also developing potential antiviral therapies against COVID-19, including FUJOVEE (Abivertinib) and its rapid diagnostic test, including COVIMARK.

GREY:SRNE - Post by User

Sorrento Therapeutics Inc

<< Previous

Bullboard Posts

Next >>

Post by TheeRookon Jun 25, 2021 5:29pm

261 Views

Post# 33454649

EUA Approval and Import License From Mexico Authority COFEPR

Sorrento Receives EUA Approval and Import License From Mexico Authority COFEPRIS For COVI-STIX ™ (COVID-19 Virus Rapid Antigen Detection Test) and Plans Product Launch With Initial Shipments in July

2021-06-24 10:14 PT - News Release

Sorrento received official EUA registration and product import license: COFEPRIS EUA registration number “OFICIO: CAS/10720/2021”.

Sorrento is establishing its “Sorrento Mexico Ltd” subsidiary to enable commercialization of COVI-STIX™ and future COVID-19 related products in the country.

Sorrento expects the first shipments for initial COVI-STIX test orders to be delivered in July.

<< Previous

Bullboard Posts

Next >>

Mullen Group: Navigates market challenges towards success